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Nucleophosmin-anaplastic lymphoma kinase (NPM–ALK) is a
tyrosine kinase oncogene responsible for the pathogenesis of
the majority of human ALK-positive lymphomas. We recently
reported that it activated the Rac1 GTPase in anaplastic large-
cell lymphoma (ALCL), leading to Rac-dependent formation of
active invadopodia required for invasiveness. Herein, we went
further into the study of this pathway and used the inhibitor of
Rac, NSC23766, to validate its potential as a molecular target in
ALCL in vitro and in vivo in a xenograft model and in a
conditional model of NPM–ALK transgenic mice. Our data
demonstrate that Rac regulates important effectors of NPM–
ALK-induced transformation such as Erk1/2, p38 and Akt.
Moreover, inhibition of Rac signaling abrogates NPM–ALK-
elicited disease progression and metastasis in mice, high-
lighting the potential of small GTPases and their regulators as
additional therapic targets in lymphomas.
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Introduction
Translocation of the gene encoding the anaplastic lymphoma
kinase (ALK) located on chromosome 2p23 results in the
expression of chimera proteins (about 17 characterized so far)
associated with various cases of non-Hodgkin’s lymphomas
with a high grade of malignancy. The most frequent rearrange-
ment, a t(2;5) (p23;q35) reciprocal translocation, fuses the
N-terminal portion of nucleophosmin 1 (NPM) to the C-terminal
portion of ALK that contains the catalytic domain to produce the
NPM–ALK fusion protein, which constitutive tyrosine kinase
activity accounts for transformation.
1,2 The majority of ALK
translocations leads to hematological malignancies of the
anaplastic large-cell lymphoma subtype (ALCL), but cases of
diffuse large B-cell lymphomas and myeloproliferative leukemia
have been described.
3,4 ALK is also expressed in a subset of
primary solid cancers, either as the result of translocation or as a
full-length intact or mutated protein. It has been found in
inﬂammatory myoﬁbroblastic tumors, non-small lung cancers,
melanoma, breast carcinoma and neural tumors (neuro-
blastoma, neuroectodermal tumors or glioblastomas).
5 Several
groups have undertaken the study of molecular factors involved
in ALK-dependent tumorigenesis. Many modulators, down-
stream effectors and associated oncogenes were identiﬁed and
characterized. NPM–ALK functions as a scaffold that recruits a
‘signalosome’ of more than 40 proteins, involved in activation of
proliferative and antiapoptotic responses, which have been
extensively studied.
5–7 The majority of ALK (þ) ALCL are
diagnosed at advanced III and IV stages, displaying systemic
disease with a high propensity for extranodal dissemination,
especially in the skin and soft tissues such as the liver, lung or
spleen, clearly identifying ALK (þ) malignancies as very
invasive neoplasms.
2,8–11 Understanding the synergy between
ALK and its signaling partners should facilitate the design of
innovative therapeutic strategies.
Recently, regulators of cytoskeleton dynamics such as the
Rho GTPases Rac1 and its activator the guanine-nucleotide
exchange factor (GEF) Vav3, p130Cas and pp60
c src have been
implicated in NPM–ALK-dependent invasion.
8,9,12 Ambrogio
et al.
13 demonstrated that the Vav1/Cdc42 signaling cascade
regulated NPM–ALK (þ) cells survival and migration. Rho
GTPases mediate many aspects of cell biology including
proliferation, regulation of the apoptosis/survival balance,
polarity, adhesion, membrane trafﬁcking and motility.
14 The
high incidence of overexpression of some of them (RhoA, RhoC,
Rac1, Rac3 and Cdc42) or their regulators in human tumors
suggests that GTPases are important in the carcinogenesis
process.
15 Targeting Rho GTPases in mice has allowed to better
understand their physiological role in vivo.
16
Our previous studies demonstrated the implication of Rac1 in
mediating NPM–ALK-dependent invasion of ALCL cells.
9
Importantly, we unraveled a central role for Rac in the
structuration of functional invadopodia by allowing secretion
of the metalloproteinase MMP-9 and the establishment of the
CD44/MMP-9/Hsp90 complex that drives extracellular matrix
degradation and 3D migration of NPM–ALK (þ) cells in vitro.
17
Herein, we sought to investigate whether inhibition of Rac by
NSC23766, a small molecule inhibitor demonstrated to
reproduce the effects of genetic invalidation of Rac1 and Rac2
in mice, could affect the tumorigenicity of NPM–ALK (þ) cells
and the development of the disease in a xenograft model of
ALCL and in NPM–ALK-expressing transgenic mice.
Materials and methods
Reagents and antibodies
Cell culture reagents were purchased from Invitrogen (Carlsbad,
CA, USA). WHI-154 and NSC23766 were from Calbiochem
(San Diego, CA, USA). Aprotinin and leupeptin were from
Euromedex (Souffelweyersheim, France). All other chemicals
were from Sigma-Aldrich (St Louis, MO, USA). The following
antibodies were used in this study: ALK (Sp8; Abcam,
Cambridge, UK), B220/CD45R (RA3-6B2; AbD Serotec, Colmar,
France), Rac1 (23A8; Upstate Biotechnology, Lake Placid, NY,
USA), phospho-ALK-Y1604 (recognizes Y664 on NPM–ALK), Received 30 March 2011; accepted 15 April 2011
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Erk1/2, phospho-STAT3-Y705, STAT3, phospho-Akt-S473, Akt
were all from Cell Signaling Technologies (Beverly, MA, USA).
Horseradish peroxidase (HRP)-conjugated secondary antibodies
were from Promega (Madison, WI, USA).
Mice
The generation of tTA/pBIL-NA transgenic mice expressing
NPM–ALK under the tetracyclin regulatory system was pre-
viously described.
18 Expression of the NPM–ALK transgene was
obtained by removing doxycycline (100mg/ml) from the drink-
ing water. Animals used in the experiments were littermates.
Female SCID (C.B-17-Prkdc
scid/lcrCrl) mice obtained from
‘Centre d’Elevage Janvier’ (Le Genest St Isle, France) were used
at age 7–12 weeks. Mice were housed in the animal facility of
INSERM U1043 (Purpan Hospital, Toulouse, France) under
speciﬁc pathogen-free conditions. Experiments were conducted
according to animal protocols approved by the INSERM.
Cell culture
Human ALCLs cell lines Karpas 299 and Cost were cultured in
Iscove-modiﬁed Dulbecco medium (IMDM) supplemented with
15% fetal calf serum, 100U/ml penicillin, 100mg/ml strepto-
mycin at 371C, in a humidiﬁed atmosphere of 5% carbon
dioxide. Cost ALCL cell line
19 was obtained from G Delsol
(CRCT, Toulouse, France). Karpas 299 ALCL cells were obtained
from DSMZ (German Collection of Microorganisms and Cell
Culture, Braunschweig, Germany). Cell lines were checked
twice a month for Mycoplasma (MycoAlert Mycoplasma
detection assay, Lonza, Basel, Switzerland).
Immunoblotting
Total cellular proteins were extracted with 50mM Tris-base
pH 8, 150mM NaCl, 5mM EGTA, 1% Nonidet P-40, 1mM
PMSF, 50mM NaF, 1mM Na3VO4,1 0mg/ml leupeptin and 2mg/
ml aprotinin. Proteins were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis followed by western blotting
on Immobilon-P membranes (Millipore, Billerica, MA, USA)
with appropriate antibodies. Immunoreactive bands were
detected by chemiluminescence with the SuperSignal detection
system (Pierce Chemical Co, Rockford, IL, USA).
Matrigel invasion assays
The Matrigel invasion assay measures the ability of ALCLs to
invade a dense Matrigel matrix (BD Biosciences, Rockville, MD,
USA) that mimicks the basement membranes. A total of 2 10
5
overnight serum-starved ALCLs cells were labeled for 90min
with 0.5mM CellTracker Orange CMTMR (Invitrogen). After
washes, cells were seeded in labtek chambers and overlaid with
Matrigel at 5mg/ml, þ/  40mM NSC23766. After 90min at
371C, medium containing 15% fetal calf serum and 1mg/ml
SDF1a was added. After 24h, cells were analyzed by confocal
microscopy (LSM510, Carl Zeiss, Oberkochen, Germany) using
a2 0   objective. Optical z sections were taken every 2.5mm
starting from the base and extending 100mm into the Matrigel.
To quantify invasion, CMTMR ﬂuorescent cells in the sections
above 20mm were added and then divided by the sum of cells in
all the z sections. Data represent the analysis of X200 cells per
condition. Three-dimentional imaging and cell quantiﬁcation
were realized using the Imaris 6.4.2 software (Bitplane AG,
Zurich, Switzerland).
In vivo tumorigenicity assays
Karpas 299 cells were centrifuged and resuspended in 150mlo f
phosphate-buffered saline (PBS) before being injected subcuta-
neously into SCID mice (6 10
6 cells per animal). Tumors were
let to develop for 7 days, then mice were treated twice a day by
intraperitoneal administration of PBS or 2.5mg/kg of NSC23766
for 9 additional days. Tumor development was assessed by
calliper measurements. Volume was calculated according to the
formula: length (mm) thickness (mm) width (mm) 0.52.
Results are expressed as ratio of the tumor volume at each time
point over the volume before treatment. On day 10 post-
treatment, mice were killed and dissected. Tumors and organs
were ﬁxed in 4% formalin and embedded in parafﬁn. Transgenic
tTA-pBIL-NA mice (3-weeks old) were treated with NSC23766
for 14 days as described above.
Immunohistochemistry
Sections of tissues were incubated with the following antibodies:
ALK (Sp8), or B220/CD45R. Development was described
previously.
18 Antibody binding was detected using the Impress
Rabbit Kit (Vector laboratories, Burlingame, CA, USA). Sections
were observed with a Leica DMR microscope (Leica, Solms,
Germany) at the indicated magniﬁcation.
Statistical analysis
The mean±standard error was calculated for each data point.
Data are representative of three to ﬁve independent experi-
ments. Differences between groups were analyzed by the
Student’s t-test. In all cases, Po0.001.
Results
Rac controls transforming properties of NPM–ALK (þ)
cells in vitro
We had previously shown that expression of the dominant
negative Rac1-T17N mutant abrogated invasion of NPM–ALK
(þ) ﬁbroblasts.
9 We used the Rac small-molecule inhibitor
NSC23766 to analyze its effects on NPM–ALK-induced inva-
siveness in vitro in NPM–ALK (þ) ALCL cell lines Cost (small-
cells variant) and Karpas 299 (common type).
20 Overnight
treatment with 40mM NSC23766 resulted in the blockade of
Rac1-GTP loading, while RhoA and Cdc42 were unaffected
(Supplementary Figure 1).
NPM–ALK has been reported to affect cell morphology,
adhesion and migration in various cell types. In ALCL cells
invading 3D-Matrigel, NPM–ALK transformation led to the
formation of dynamic membrane protrusions around the cellular
body, which display polarized motile actin-rich membrane
protrusions towards a SDF1a gradient.
17 We then proceeded to
evaluating whether NPM–ALK-dependent invasion was affected
by NSC23766 using the same experimental set-up. Figure 1
showed that treatment of Cost and Karpas 299 NPM–ALK (þ)
ALCL cells with 40mM NSC23766 abolished invasion of 3D-
Matrigel, demonstrating that pharmacological inhibition of Rac
was similar to the classical dominant negative approach to block
Rac-dependent cellular responses in vitro.
The oncogenic potential of ALK fusions relies on their
hyperactive tyrosine kinase activity that activates interconnected
signaling pathways common to many oncogenic kinases.
5,11 For
instance, resistance of ALK (þ) cells to apoptosis relates to
JAK3/STAT3 and PI3 kinase/Akt pathways, while increased
proliferation is accounted for by the activation of Src family
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Blood Cancer Journalkinases, Grb2/Sos/Ras, MAPK (Erk1/2, JNK and p38 (ref. 5). As
expected, Figure 2 demonstrated that those signaling modules
were strictly dependent on ALK kinase activity as treatment of
Cost and Karpas 299 with the WHI-154 inhibitor led to their
inactivation. Because some of those NPM–ALK targets were
described as Rac downstream effectors, we evaluated their
status of phosphorylation/activation upon NSC23766 treatment.
We observed a drop in p38, Erk1/2 and Akt phosphorylations
that was similar to that obtained with ALK inhibition (Figure 2).
Importantly, NPM–ALK and STAT3 activation were spared,
demonstrating that only some of the pathways known to
trigger ALK-dependent transformation were under the regulation
of Rac.
Rac drives invasion of NPM–ALK (þ) ALCL in vivo
The main advantage of using a selective pharmacological
inhibitor is its capacity to be used in animal models. To
evaluate the impact of Rac1 signaling on in vivo transforming
properties of NPM–ALK, Karpas 299 cells were subcutaneously
engrafted in immunocompromised SCID mice. NPM–ALK (þ)
cells gave rise to rapidly growing tumors within 7 days.
Thereafter, animals were injected twice a day with intraper-
itoneal doses of 2.5mg/kg NSC23766 (NSC23766 mice) or PBS
(PBS mice).
We observed that NSC23766 treatment blocked tumor
development (volume¼34±12mm
3, 9 days post-treatment) in
contrast to PBS-injected mice in that tumor growth still
progressed (volume¼436±14mm
3, Figures 3a and b). The
tumors from the PBS mice had indistinct margins and several
foci of necrosis, typical of fast developing neoplasia, whereas
tumors from NSC mice were small with distinct margins.
Immunohistochemistry demonstrated that both types of sub-
cutaneous tumors were formed by Karpas 299 displaying the
characteristic phenotype of large NPM–ALK (þ) cells (Figure 4).
Macroscopic observations of the organs after autopsy revealed
marked splenomegaly and lymphadenopathy suggesting a
dissemination of Karpas 299 cells from the original subcuta-
neous tumor in PBS mice. Spleens of PBS mice reached
2.3±0.3mm, while it was reverted to normal size of
1.4±0.1mm in NSC23766-treated mice (Figures 3c and d). To
better assess the extent of dissemination, immunohistochemistry
with anti-ALK antibody was performed on tissue sections from
subcutaneous tumor, lymph node (LN), spleen, lung and liver,
which correspond to sites of metastasis usually found in human
disease.
11 Figure 4 (upper panel) showed that Karpas 299 cells
Karpas Cost
p38
Erk1/2
p-p38(T180/Y182)
p-STAT3(Y705)
STAT3
p-Erk1/2(T202/Y204)
p-Akt(S473)
Akt
NPM-ALK
p-NPM-ALK(Y664)
NSC23766 - + - - + -
WHI-154 - - + - - +
Figure 2 Rac is involved in NPM–ALK-mediated activation of
signaling cascades. Serum-starved Karpas 299 or Cost cells were
treated overnight with 15mM of WHI-154 or 40mM of NSC23766.
Lysates were then analyzed by immunoblotting with the indicated
speciﬁc antibodies. Antibodies to total proteines analyzed were used
as loading controls. Data are representative of three to four
independent experiments.
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Figure 3 Inhibition of Rac downregulates growth and spreading of
xenografted NPM–ALK (þ) Karpas 299 tumors. Karpas 299 cells were
subcutaneously injected into SCID mice. Tumor development was
allowed for 7 days, before 9 days of treatment with NSC23766 (two
intraperitoneal injections per day, 2.5mg/kg). (a) Black and white
pictures of subcutaneous tumor masses after 9 days of treatment, doted
circle delineate the tumors. (b) Tumor development was assessed by
calliper measurements, data are presented as the percentage of the
tumor volume at the indicated time over the size at D0 (when
treatment was started). Data are from groups of ﬁve (PBS) and seven
(NSC23766) mice. (c) Spleen enlargements of PBS- or NSC23766-
treated littermates are shown. (d) The histogram represents the
mean±s.e.m. of spleen size.
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Figure 1 Rac regulates NPM–ALK-dependent invasiveness in vitro.
Invasion of NPM–ALK (þ) ALCLs cells treated with PBS or 40mM of
the Rac inhibitor NSC23766 into Matrigel. Invading cells were stained
with CMTMR and visualized by confocal microscopy. The number of
cells penetrating the Matrigel to depths of 20mm and greater was
expressed as a percentage of the total cell number within the gel.
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Blood Cancer Journalwere found in all tested organs in control PBS mice,
demonstrating that subcutaneously xenografted ALCL cells were
highly invasive. Conversely, none of the NSC23766-injected
mice showed signs of ALK-staining in distant organs, while
about a fourth of them (3 out of 11 mice) still showed a slight LN
inﬁltration on the side of tumoral engraftment (Figure 4, lower
panel). These data indicate that the Rac pathway has a central
role in regulating tumoral growth, as well as invasiveness of
NPM–ALK (þ) ALCL cells in xenografted mice models.
Pharmacological inhibition of Rac impairs lymphoma
development in transgenic mice
To better assess the impact of inhibiting Rac-dependent
signaling on ALK (þ) pathogenesis, we took advantage of a
recently developed conditional transgenic mice model of ALK-
induced lymphomagenesis that uses the tetracycline regulatory
system under the control of the EmSra enhancer/promoter. In this
model, the expression of NPM–ALK induces B-cell lymphoma/
leukemia and the development of skin keratoacanthoma-like
lesions resulting from aberrant expression of the transgene in
keratinocytes.
18 Even though it does not reproduce faithfully the
human disease, this model represents a major tool to investigate
in vivo molecular mechanisms involved in ALK-associated
disorders, and to test putative therapeutic targets. On expression
of NPM–ALK by retrieving doxycycline from the drinking water
at birth, mice develop the disease around 3 weeks of age. It is
characterized by a typical skin disorder that affects snout and
paws (Figure 5a), growth defects (Figure 5b) and general
lymphoid malignancy with marked splenomegaly and lympha-
denopathy (Figure 5c), with death happening between 4 and 5
weeks.
18 Mice (3-weeks old) that just showed the ﬁrst signs of
the disease were treated either by injections of NSC23766 or
PBS as a control. At 5 weeks of age, although control littermates
were dying, NSC mice were physically active, gained weight
and exhibited a regression of the skin lesions within a few days
of treatment (Figures 5a and b). Accordingly, LNs and spleens
regained their normal size (Figure 5c). Regression of the
lymphoid disease was conﬁrmed by immunohistochemistry.
Figure 6 showed that the architecture of the LNs of tTA/pBIL-NA
mice was obliterated by inﬁltration of tumoral cells of B origin in
this model as shown by the positive staining of the CD45R/B220
antibody. These cells were also expressing NPM–ALK. Inhibition
of Rac by NSC23766 restored the normal architecture of the LNs
and markedly reduced the inﬁltration by NPM–ALK/B220-
positive lymphoma cells, which became similar to what was
observed when the oncogene was repressed by doxycyline
administration (Figure 6). Analysis of the peripheral organs
(spleen, lung and liver) demonstrated a marked regression or
disappearance of inﬁltrating lymphoma cells (Figure 7). Alto-
gether, these data demonstrate the major role of Rac in
lymphomagenesis and dissemination of NPM–ALK mali-
gnancies. The effects of NSC23766 provide a rationale for
targeting small GTPases in ALK-dependent cancers.
Discussion
If the roles of Rho GTPases have been well described in the
physiology of adherent cells and their involvement in solid
tumors is documented, a lot remains to be study regarding their
part in hematopoiesis and hemopathies. Speciﬁc pathways
regulated by GTPases were shown to be crucial for hemato-
poietic stem cells, T- and B-cells maturation and functions.
Small GTPases are known effectors of T- and B-lymphocytes
where they partake in activation through cytoskeleton rearran-
gements, polarization and formation of the immunological
synapse required for efﬁcient lymphocyte response.
21 These
observations account for the deregulations of Rho GTPases
associated with hematological malignancies such as leukemia,
non-Hodgkin’s lymphomas or ALCL as well as immune
pathologies. Even though they lack the TCR/BCR and most of
the signaling relays of stimulated lymphocytes, ALCL display the
phenotype of activated T- or B-cell, and NPM–ALK oncogenesis
involves pathways shared with lymphocytes activation.
22 In this
context, we and others produced a series of papers demonstrat-
ing the involvement of Rac and Cdc42 in cytoskeleton
rearrangements and proliferation that drive invasiveness of
ALK (þ) ALCL, thereby opening new therapeutic perspec-
tives.
9,13,17 In this study, we demonstrated that NSC23766
treatment resulted in a blockade of ALCL-derived cell lines
invasion of 3D-Matrigel, identifying Rac as a major relay of
NPM–ALK-dependent invasive properties.
NSC23766 emerged as a powerful tool as it displays no
signiﬁcant toxicity in mice even after weeks of daily adminis-
tration.
23 Therefore, we treated mice that had developed
subcutaneous tumors formed by the human NPM–ALK (þ)
ALCL cell line Karpas 299 by daily doses of NSC23766. Even
though we did not observe any regression, the growth and
spreading of the tumors harbored by NSC23766-treated mice
X 400
LN spleen
PBS
tumor
NSC23766
liver lung
Figure 4 Rac inhibition prevents dissemination of subcutaneous Karpas 299 tumors. Mice were killed after 9 days of treatment, tumors and the
indicated organs were harvested, ﬁxed and parafﬁn embedded for subsequent immunohistochemical analysis with the anti-ALK (Sp8) antibody.
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Blood Cancer Journalwere totally blocked compared with control animals. A similar
experiment was conducted by the group of Chiarle who
investigated the role of Cdc42 in the growth and maintenance
of subcutaneously engrafted ALK (þ) tumors. In this study, they
identiﬁed Cdc42 as an important regulator of tumor develop-
ment. Inhibition of Cdc42, either by small hairpin RNA or by the
Secramine A inhibitor lead to cell death over time. We did not
detect any apoptosis in our models (not shown). This could be
explained by the persistent STAT3 activation under NSC23766,
even though MAPK family members (p38 and Erk1/2) and Akt
NPM–ALK-dependent activation was abolished. As a target of
NPM–ALK, STAT3 has a major role in ALCL tumorigenesis by
increasing the transcription of antiapoptotic factors and cell-
cycle regulators such as BCL-XL, cyclin D3 or C/EBPb,t o
increase survival and proliferation.
24 Therefore, its inactivation
might be required to induce apoptosis of NPM–ALK (þ) cells.
We then took a step forward by using newly developed
conditional transgenic mice for ALK-induced lymphomagenesis
under the tetracycline regulatory system. In this model as in many
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Figure 5 Macroscopic observation of the regression of the disease of
NSC23766-treated NPM–ALK-expressing tTA/pBIL-NA transgenic
mice. Expression of the NPM–ALK transgene was induced by removing
dox from the drinking water of newborn transgenic mice. After 3
weeks, mice were treated twice a day by intraperitoneal injection of
PBS or 2.5mg/kg of NSC23766. (a) Black and white pictures of
littermate mice showing the decrease in size and the development
of keratoacanthoma-like lesions on the snout and paws of PBS control
mice. NSC23766 treatment reverses the phenotypes. (b) Measure-
ments of the size increase generated by NSC23766 administration.
(c) Rac inhibition reverted the typical spleen and LNs enlargements
observed in transgenic mice.
PBS
NSC23766
LN
B220
B220
ALK
ALK
Dox
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ALK
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Figure 6 Rac inhibition induces histophatological changes of lymph
nodes of NPM–ALK transgenic mice comparable to oncogene
silencing by re-administration of doxycycline. A 3-weeks-old tTA/
pBIL-NA mice expressing NPM–ALK were treated for 14 days with
NSC23766 as previously described. Mice were killed and LNs
harvested, ﬁxed and parafﬁn embedded for immunohistochemical
analysis with the anti-ALK (Sp8) and the anti-B220 (B-lymphocytes)
antibodies. The architecture of LN from PBS mice with a fully
developped disease was obliterated by lymphoma cells positive for
both B220 and ALK. Upon NSC23766 administration (NSC23766
mice), the LN progressively recovers a normal architecture, with a
decrease of ALK (þ) cells and an increase in B- (B220 positive) and
T-cells (blue areas) similar to dox treatment (dox).
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oncogene causes B-cells lymphomas. It offers a powerful tool to
investigate in vivo the mechanisms associated with ALK-induced
transformation and therapeutic options, which was illustrated as a
proof of principle by the use of the ALK inhibitor PF-02341066.
18
Administration of NSC23766 to transgenic mice that were starting
to develop the disease blocked the development of the lymphoid
malignancy and signiﬁcantly reduced the keratoacanthoma-like
lesions (Supplementary Figure 2) observed in this model.
Metastasis of target organs was totally abrogated, demonstrating
that treatment with this ﬁrst-generation Rac inhibitor was of major
interest in ALK-driven malignancies. We tested several modes of
administration of the drug. Intraperitoneal injections were con-
ducted in parallel to delivery with Azlet osmotic pumps (one
pump, 50mM NSC23766). Both treatments gave the same results,
the intraperitoneal administration being slightly more efﬁcient,
probably due to the short life-time of NSC23766 that is likely
inactivated by remaining at the mouse body temperature over 2
weeks when delivered through the pumps. It has to be noted that
NSC23766 was already shown to limit the development of BCR-
ABL (þ) chronic myeloid leukemia, even in the case of cells that
were resistant to the Abl inhibitor classically used in therapy,
imatinib. Thomas et al.
23 demonstrated that co-administration of
low doses of NSC23766 and imatinib signiﬁcantly affected the
development of the disease. These data clearly suggest that
targeting Rac is a valid option for the treatment of various
hematological malignacies. Indeed, the ALK inhibitor
PF-02341066 (crizotinib) has just started to enter clinical trial to
target the EML4-ALK kinase in non-small-cell lung cancer, and
mutations in the kinase domain conferring resistance to the
treatment have just been reported.
25,26 In this context, it is a major
importance to be able to implement multi-target therapies to
increase the chances of eradicating the disease.
To conclude, this work identiﬁed the Rac1 pathway as being
important for the dissemination of the disease and establishment
of metastasis in vivo. Our data together with the literature place
Rho GTPases at the center of blood malignancies. It highlights
the fact that the development of inhibitors of this family of
proteins is a promising and valid option for therapeutic
intervention in both lymphoma and leukemia.
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